{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,17]],"date-time":"2026-01-17T22:40:41Z","timestamp":1768689641391,"version":"3.49.0"},"reference-count":65,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T00:00:00Z","timestamp":1732233600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970806"],"award-info":[{"award-number":["81970806"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["81970806"],"award-info":[{"award-number":["81970806"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-024-03358-5","type":"journal-article","created":{"date-parts":[[2024,11,22]],"date-time":"2024-11-22T16:59:49Z","timestamp":1732294789000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":5,"title":["Advances of IGF-1R inhibitors in Graves\u2019 ophthalmopathy"],"prefix":"10.1007","volume":"44","author":[{"given":"Meilan","family":"Wang","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lian","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2024,11,22]]},"reference":[{"issue":"9","key":"3358_CR1","doi-asserted-by":"publisher","first-page":"1970","DOI":"10.3390\/cells9091970","volume":"9","author":"T Yoshida","year":"2020","unstructured":"Yoshida T, Delafontaine P (2020) Mechanisms of IGF-1-mediated regulation of skeletal muscle hypertrophy and atrophy. Cells 9(9):1970. https:\/\/doi.org\/10.3390\/cells9091970","journal-title":"Cells"},{"issue":"2","key":"3358_CR2","doi-asserted-by":"crossref","first-page":"151902","DOI":"10.1016\/j.imbio.2019.151902","volume":"225","author":"JS Paik","year":"2020","unstructured":"Paik JS, Kim S-E, Kim JH et al (2020) Insulin-like growth factor-1 enhances the expression of functional TSH receptor in orbital fibroblasts from thyroid-associated ophthalmopathy. Immunobiology 225(2):151902","journal-title":"Immunobiology"},{"issue":"4","key":"3358_CR3","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1056\/NEJMoa1910434","volume":"382","author":"RS Douglas","year":"2020","unstructured":"Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341\u2013352","journal-title":"N Engl J Med"},{"issue":"9","key":"3358_CR4","doi-asserted-by":"publisher","first-page":"3203","DOI":"10.3390\/jcm12093203","volume":"12","author":"EW Lai","year":"2023","unstructured":"Lai EW, Tai YH, Hsiang-Ling W, Dai YX, Chen TJ, Cherng YG, Lai SC (2023) The association between autoimmune thyroid disease and ocular surface damage: a retrospective population-based cohort study. J Clin Med 12(9):3203. https:\/\/doi.org\/10.3390\/jcm12093203","journal-title":"J Clin Med"},{"issue":"20","key":"3358_CR5","doi-asserted-by":"crossref","first-page":"1468","DOI":"10.1056\/NEJM199311113292007","volume":"329","author":"RS Bahn","year":"1993","unstructured":"Bahn RS, Heufelder AE (1993) Pathogenesis of Graves\u2019 ophthalmopathy. N Engl J Med 329(20):1468\u20131475","journal-title":"N Engl J Med"},{"issue":"4","key":"3358_CR6","doi-asserted-by":"crossref","first-page":"G43","DOI":"10.1530\/EJE-21-0479","volume":"185","author":"L Bartalena","year":"2021","unstructured":"Bartalena L, Kahaly GJ, Baldeschi L et al (2021) The 2021 European Group on Graves\u2019 orbitopathy (EUGOGO) clinical practice guidelines for the medical management of Graves\u2019 orbitopathy. Eur J Endocrinol 185(4):G43\u2013G67","journal-title":"Eur J Endocrinol"},{"issue":"5","key":"3358_CR7","doi-asserted-by":"crossref","first-page":"D27","DOI":"10.1530\/EJE-19-0389","volume":"181","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Bartalena L (2019) Will biological agents supplant systemic glucocorticoids as the first-line treatment for thyroid-associated ophthalmopathy? Eur J Endocrinol 181(5):D27\u2013D43","journal-title":"Eur J Endocrinol"},{"issue":"3","key":"3358_CR8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1530\/EJE-14-0712","volume":"172","author":"E Sisti","year":"2015","unstructured":"Sisti E, Coco B, Menconi F et al (2015) Intravenous glucocorticoid therapy for Graves\u2019 ophthalmopathy and acute liver damage: an epidemiological study. Eur J Endocrinol 172(3):269\u2013276","journal-title":"Eur J Endocrinol"},{"issue":"2","key":"3358_CR9","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/S2213-8587(16)30046-8","volume":"5","author":"WM Wiersinga","year":"2017","unstructured":"Wiersinga WM (2017) Advances in treatment of active, moderate-to-severe Graves\u2019 ophthalmopathy. Lancet Diabetes Endocrinol 5(2):134\u2013142","journal-title":"Lancet Diabetes Endocrinol"},{"issue":"16","key":"3358_CR10","doi-asserted-by":"crossref","first-page":"1552","DOI":"10.1056\/NEJMra1510030","volume":"375","author":"TJ Smith","year":"2016","unstructured":"Smith TJ, Heged\u00fcs L (2016) Graves\u2019 disease. N Engl J Med 375(16):1552\u20131565","journal-title":"N Engl J Med"},{"issue":"8","key":"3358_CR11","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1056\/NEJMra0905750","volume":"362","author":"RS Bahn","year":"2010","unstructured":"Bahn RS (2010) Graves\u2019 ophthalmopathy. N Engl J Med 362(8):726\u2013738","journal-title":"N Engl J Med"},{"issue":"3","key":"3358_CR12","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1530\/JME-11-0006","volume":"46","author":"S Kumar","year":"2011","unstructured":"Kumar S, Nadeem S, Stan MN et al (2011) A stimulatory TSH receptor antibody enhances adipogenesis via phosphoinositide 3-kinase activation in orbital preadipocytes from patients with Graves\u2019 ophthalmopathy. J Mol Endocrinol 46(3):155\u2013163","journal-title":"J Mol Endocrinol"},{"issue":"9","key":"3358_CR13","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.1210\/en.2013-1576","volume":"154","author":"S Moshkelgosha","year":"2013","unstructured":"Moshkelgosha S, So P-W, Deasy N et al (2013) Cutting edge: retrobulbar inflammation, adipogenesis, and acute orbital congestion in a preclinical female mouse model of Graves\u2019 orbitopathy induced by thyrotropin receptor plasmid-in vivo electroporation. Endocrinology 154(9):3008\u20133015","journal-title":"Endocrinology"},{"issue":"1","key":"3358_CR14","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1210\/jc.2009-1614","volume":"95","author":"RS Douglas","year":"2010","unstructured":"Douglas RS, Afifiyan NF, Hwang CJ et al (2010) Increased generation of fibrocytes in thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 95(1):430\u2013438","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3358_CR15","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1210\/er.2018-00066","volume":"40","author":"TJ Smith","year":"2019","unstructured":"Smith TJ, Janssen JAMJL (2019) Insulin-like growth factor-I receptor and thyroid-associated ophthalmopathy. Endocr Rev 40(1):236\u2013267","journal-title":"Endocr Rev"},{"issue":"2","key":"3358_CR16","doi-asserted-by":"crossref","first-page":"101773","DOI":"10.1016\/j.beem.2023.101773","volume":"37","author":"SM Ferrari","year":"2023","unstructured":"Ferrari SM, Paparo SR, Ragusa F et al (2023) Chemokines in thyroid autoimmunity. Best Pract Res Clin Endocrinol Metab 37(2):101773","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"3358_CR17","doi-asserted-by":"crossref","first-page":"629925","DOI":"10.3389\/fendo.2020.629925","volume":"11","author":"A George","year":"2020","unstructured":"George A, Diana T, L\u00e4ngericht J et al (2020) Stimulatory thyrotropin receptor antibodies are a biomarker for Graves\u2019 orbitopathy. Front Endocrinol (Lausanne) 11:629925","journal-title":"Front Endocrinol (Lausanne)"},{"issue":"6","key":"3358_CR18","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1001\/jamaophthalmol.2018.0806","volume":"136","author":"G Rotondo Dottore","year":"2018","unstructured":"Rotondo Dottore G, Torregrossa L, Caturegli P et al (2018) Association of T and B cells infiltrating orbital tissues with clinical features of Graves orbitopathy. JAMA Ophthalmol 136(6):613\u2013619","journal-title":"JAMA Ophthalmol"},{"issue":"3","key":"3358_CR19","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1038\/s41423-020-00615-2","volume":"18","author":"Y Wang","year":"2021","unstructured":"Wang Y, Chen Z, Wang T et al (2021) A novel CD4 + CTL subtype characterized by chemotaxis and inflammation is involved in the pathogenesis of Graves\u2019 orbitopathy. Cell Mol Immunol 18(3):735\u2013745","journal-title":"Cell Mol Immunol"},{"key":"3358_CR20","doi-asserted-by":"publisher","first-page":"101706","DOI":"10.1016\/j.molmet.2023.101706","volume":"71","author":"K Wissmiller","year":"2023","unstructured":"Wissmiller K, Bilekova S, Franko A, Lutz SZ, Katsburg M, Gulde S, Pellegata NS, Stenzl A et al (2023) Inceptor correlates with markers of prostate cancer progression and modulates insulin\/IGF1 signaling and cancer cell migration. Mol Metab 71:101706. https:\/\/doi.org\/10.1016\/j.molmet.2023.101706","journal-title":"Mol Metab"},{"issue":"3","key":"3358_CR21","doi-asserted-by":"crossref","first-page":"e0282512","DOI":"10.1371\/journal.pone.0282512","volume":"18","author":"S Roche","year":"2023","unstructured":"Roche S, Gaule P, Winrow D et al (2023) Preclinical evaluation of Insulin-like growth factor receptor 1 (IGF1R) and insulin receptor (IR) as a therapeutic targets in triple negative breast cancer. PLoS ONE 18(3):e0282512","journal-title":"PLoS ONE"},{"issue":"1","key":"3358_CR22","first-page":"50","volume":"17","author":"HJ Lee","year":"2018","unstructured":"Lee HJ, Pham PC, Hyun SY et al (2018) Development of a 4-aminopyrazolo[3,4-d]pyrimidine-based dual IGF1R\/Src inhibitor as a novel anticancer agent with minimal toxicity. Mol Cancer 17(1):50","journal-title":"Mol Cancer"},{"issue":"4","key":"3358_CR23","doi-asserted-by":"publisher","first-page":"3665","DOI":"10.3390\/ijms24043665","volume":"24","author":"A Kasprzak","year":"2023","unstructured":"Kasprzak A (2023) Autophagy and the insulin-like growth factor (IGF) system in colonic cells: implications for colorectal neoplasia. Int J Mol Sci 24(4):3665. https:\/\/doi.org\/10.3390\/ijms24043665","journal-title":"Int J Mol Sci"},{"issue":"2","key":"3358_CR24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1002\/path.6033","volume":"259","author":"J Zhang","year":"2023","unstructured":"Zhang J, Chen B, Li H et al (2023) Cancer-associated fibroblasts potentiate colorectal cancer progression by crosstalk of the IGF2-IGF1R and Hippo-YAP1 signaling pathways. J Pathol 259(2):205\u2013219","journal-title":"J Pathol"},{"issue":"4","key":"3358_CR25","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1158\/1541-7786.MCR-19-0956","volume":"18","author":"T Manabe","year":"2020","unstructured":"Manabe T, Yasuda H, Terai H et al (2020) IGF2 autocrine-mediated IGF1R activation is a clinically relevant mechanism of osimertinib resistance in lung cancer. Mol Cancer Res 18(4):549\u2013559","journal-title":"Mol Cancer Res"},{"issue":"2","key":"3358_CR26","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1124\/pr.109.002469","volume":"62","author":"TJ Smith","year":"2010","unstructured":"Smith TJ (2010) Insulin-like growth factor-I regulation of immune function: a potential therapeutic target in autoimmune diseases? Pharmacol Rev 62(2):199\u2013236","journal-title":"Pharmacol Rev"},{"issue":"4","key":"3358_CR27","doi-asserted-by":"publisher","first-page":"650","DOI":"10.1016\/j.immuni.2020.03.013","volume":"52","author":"D DiToro","year":"2020","unstructured":"DiToro D, Harbour SN, Bando JK, Benavides G, Witte S, Laufer VA, Moseley C, Singer JR et al (2020) Insulin-like growth factors are key regulators of T helper 17 regulatory T cell balance in autoimmunity. Immunity 52(4):650-667.e10. https:\/\/doi.org\/10.1016\/j.immuni.2020.03.013","journal-title":"Immunity"},{"issue":"7630","key":"3358_CR28","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1038\/nature20141","volume":"539","author":"CZ Han","year":"2016","unstructured":"Han CZ, Juncadella IJ, Kinchen JM et al (2016) Macrophages redirect phagocytosis by non-professional phagocytes and influence inflammation. Nature 539(7630):570\u2013574","journal-title":"Nature"},{"issue":"7","key":"3358_CR29","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/s41419-022-05074-3","volume":"13","author":"A Rajala","year":"2022","unstructured":"Rajala A, Teel K, Bhat MA et al (2022) Insulin-like growth factor 1 receptor mediates photoreceptor neuroprotection. Cell Death Dis 13(7):613","journal-title":"Cell Death Dis"},{"key":"3358_CR30","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1016\/j.phrs.2019.04.021","volume":"144","author":"J Zhang","year":"2019","unstructured":"Zhang J, Liu M, Huang M et al (2019) Ginsenoside F1 promotes angiogenesis by activating the IGF-1\/IGF1R pathway. Pharmacol Res 144:292\u2013305","journal-title":"Pharmacol Res"},{"issue":"8","key":"3358_CR31","doi-asserted-by":"crossref","first-page":"e52977","DOI":"10.15252\/embr.202152977","volume":"23","author":"SH Seo","year":"2022","unstructured":"Seo SH, Hwang S-Y, Hwang S et al (2022) Hypoxia-induced ELF3 promotes tumor angiogenesis through IGF1\/IGF1R. EMBO Rep 23(8):e52977","journal-title":"EMBO Rep"},{"issue":"2","key":"3358_CR32","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1007\/s12035-017-0386-9","volume":"55","author":"VE Lorenc","year":"2018","unstructured":"Lorenc VE, Subirada Caldarone PV, Paz MC et al (2018) IGF-1R regulates the extracellular level of active MMP-2, pathological neovascularization, and functionality in retinas of OIR mouse model. Mol Neurobiol 55(2):1123\u20131135","journal-title":"Mol Neurobiol"},{"issue":"5","key":"3358_CR33","doi-asserted-by":"publisher","first-page":"4329","DOI":"10.3390\/ijms24054329","volume":"24","author":"C Maxia","year":"2023","unstructured":"Maxia C, Isola M, Grecu E, Cuccu A, Scano A, Orr\u00f9 G, Di Girolamo N, Diana A, Murtas D (2023) Synergic action of insulin-like growth factor-2 and miRNA-483 in pterygium pathogenesis. Int J Mol Sci 24(5):4329. https:\/\/doi.org\/10.3390\/ijms24054329","journal-title":"Int J Mol Sci"},{"issue":"4","key":"3358_CR34","doi-asserted-by":"crossref","first-page":"251","DOI":"10.3109\/08916939309014643","volume":"16","author":"DR Weightman","year":"1993","unstructured":"Weightman DR, Perros P, Sherif IH et al (1993) Autoantibodies to IGF-1 binding sites in thyroid associated ophthalmopathy. Autoimmunity 16(4):251\u2013257","journal-title":"Autoimmunity"},{"issue":"12","key":"3358_CR35","doi-asserted-by":"crossref","first-page":"6348","DOI":"10.4049\/jimmunol.170.12.6348","volume":"170","author":"J Pritchard","year":"2003","unstructured":"Pritchard J, Han R, Horst N et al (2003) Immunoglobulin activation of T cell chemoattractant expression in fibroblasts from patients with Graves\u2019 disease is mediated through the insulin-like growth factor I receptor pathway. J Immunol 170(12):6348\u20136354","journal-title":"J Immunol"},{"issue":"10","key":"3358_CR36","doi-asserted-by":"crossref","first-page":"5076","DOI":"10.1210\/jc.2004-0716","volume":"89","author":"TJ Smith","year":"2004","unstructured":"Smith TJ, Hoa N (2004) Immunoglobulins from patients with Graves\u2019 disease induce hyaluronan synthesis in their orbital fibroblasts through the self-antigen, insulin-like growth factor-I receptor. J Clin Endocrinol Metab 89(10):5076\u20135080","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"3358_CR37","doi-asserted-by":"crossref","first-page":"769","DOI":"10.1210\/jc.2012-2270","volume":"98","author":"AJ Varewijck","year":"2013","unstructured":"Varewijck AJ, Boelen A, Lamberts SWJ et al (2013) Circulating IgGs may modulate IGF-I receptor stimulating activity in a subset of patients with Graves\u2019 ophthalmopathy. J Clin Endocrinol Metab 98(2):769\u2013776","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3358_CR38","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1007\/s40618-018-0943-8","volume":"42","author":"M Marino","year":"2019","unstructured":"Marino M, Rotondo Dottore G, Ionni I et al (2019) Serum antibodies against the insulin-like growth factor-1 receptor (IGF-1R) in Graves\u2019 disease and Graves\u2019 orbitopathy. J Endocrinol Invest 42(4):471\u2013480","journal-title":"J Endocrinol Invest"},{"issue":"12","key":"3358_CR39","doi-asserted-by":"crossref","first-page":"1759","DOI":"10.1007\/s40618-020-01341-2","volume":"43","author":"G Lanzolla","year":"2020","unstructured":"Lanzolla G, Ricci D, Nicol\u00ec F et al (2020) Putative protective role of autoantibodies against the insulin-like growth factor-1 receptor in Graves\u2019 Disease: results of a pilot study. J Endocrinol Invest 43(12):1759\u20131768","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"3358_CR40","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1089\/thy.2017.0105","volume":"27","author":"CC Krieger","year":"2017","unstructured":"Krieger CC, Neumann S, Marcus-Samuels B et al (2017) TSHR\/IGF-1R cross-talk, not IGF-1R stimulating antibodies mediates Graves\u2019 ophthalmopathy pathogenesis. Thyroid 27(5):746\u2013747","journal-title":"Thyroid"},{"issue":"12","key":"3358_CR41","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1089\/thy.2016.0323","volume":"26","author":"SJ Morgan","year":"2016","unstructured":"Morgan SJ, Neumann S, Marcus-Samuels B et al (2016) Thyrotropin and insulin-like growth factor 1 receptor crosstalk upregulates sodium-iodide symporter expression in primary cultures of human thyrocytes. Thyroid 26(12):1794\u20131803","journal-title":"Thyroid"},{"key":"3358_CR42","doi-asserted-by":"crossref","first-page":"107502","DOI":"10.1016\/j.pharmthera.2020.107502","volume":"209","author":"CC Krieger","year":"2020","unstructured":"Krieger CC, Neumann S, Gershengorn MC (2020) TSH\/IGF1 receptor crosstalk: mechanism and clinical implications. Pharmacol Ther 209:107502","journal-title":"Pharmacol Ther"},{"key":"3358_CR43","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.coemr.2018.01.007","volume":"2","author":"CC Krieger","year":"2018","unstructured":"Krieger CC, Morgan SJ, Neumann S et al (2018) Thyroid stimulating hormone (TSH)\/Insulin-like growth factor 1 (IGF1) receptor cross-talk in human cells. Curr Opin Endocr Metab Res 2:29\u201333","journal-title":"Curr Opin Endocr Metab Res"},{"issue":"4","key":"3358_CR44","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1111\/bph.13693","volume":"174","author":"RF Place","year":"2017","unstructured":"Place RF, Krieger CC, Neumann S et al (2017) Inhibiting thyrotropin\/insulin-like growth factor 1 receptor crosstalk to treat Graves\u2019 ophthalmopathy: studies in orbital fibroblasts in vitro. Br J Pharmacol 174(4):328\u2013340","journal-title":"Br J Pharmacol"},{"issue":"34","key":"3358_CR45","doi-asserted-by":"crossref","first-page":"4541","DOI":"10.1200\/JCO.2010.34.0000","volume":"29","author":"AS Pappo","year":"2011","unstructured":"Pappo AS, Patel SR, Crowley J et al (2011) R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration study. J Clin Oncol 29(34):4541\u20134547","journal-title":"J Clin Oncol"},{"issue":"18","key":"3358_CR46","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1056\/NEJMoa1614949","volume":"376","author":"TJ Smith","year":"2017","unstructured":"Smith TJ, Kahaly GJ, Ezra DG et al (2017) Teprotumumab for thyroid-associated ophthalmopathy. N Engl J Med 376(18):1748\u20131761","journal-title":"N Engl J Med"},{"issue":"4","key":"3358_CR47","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1089\/thy.2021.0176","volume":"32","author":"SA Morshed","year":"2022","unstructured":"Morshed SA, Ma R, Latif R et al (2022) Mechanisms in Graves eye disease: apoptosis as the end point of insulin-like growth factor 1 receptor inhibition. Thyroid 32(4):429\u2013439","journal-title":"Thyroid"},{"issue":"4","key":"3358_CR48","doi-asserted-by":"crossref","first-page":"e1653","DOI":"10.1210\/clinem\/dgab824","volume":"107","author":"CC Krieger","year":"2022","unstructured":"Krieger CC, Sui X, Kahaly GJ et al (2022) Inhibition of TSH\/IGF-1 receptor crosstalk by teprotumumab as a treatment modality of thyroid eye disease. J Clin Endocrinol Metab 107(4):e1653\u2013e1660","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"3358_CR49","doi-asserted-by":"crossref","first-page":"E1635","DOI":"10.1210\/jc.2014-1580","volume":"99","author":"H Chen","year":"2014","unstructured":"Chen H, Mester T, Raychaudhuri N et al (2014) Teprotumumab, an IGF-1R blocking monoclonal antibody inhibits TSH and IGF-1 action in fibrocytes. J Clin Endocrinol Metab 99(9):E1635\u2013E1640","journal-title":"J Clin Endocrinol Metab"},{"key":"3358_CR50","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2114244118","author":"R Fernando","year":"2021","unstructured":"Fernando R, Caldera O, Smith TJ (2021) Therapeutic IGF-I receptor inhibition alters fibrocyte immune phenotype in thyroid-associated ophthalmopathy. Proc Natl Acad Sci. https:\/\/doi.org\/10.1073\/pnas.2114244118","journal-title":"Proc Natl Acad Sci"},{"issue":"12","key":"3358_CR51","doi-asserted-by":"crossref","first-page":"4899","DOI":"10.1096\/fj.13-231381","volume":"27","author":"S Ock","year":"2013","unstructured":"Ock S, Ahn J, Lee SH et al (2013) IGF-1 receptor deficiency in thyrocytes impairs thyroid hormone secretion and completely inhibits TSH-stimulated goiter. FASEB J 27(12):4899\u20134908","journal-title":"FASEB J"},{"issue":"10","key":"3358_CR52","doi-asserted-by":"crossref","first-page":"e4037","DOI":"10.1210\/clinem\/dgac415","volume":"107","author":"R Fernando","year":"2022","unstructured":"Fernando R, Smith TJ (2022) Teprotumumab divergently alters fibrocyte gene expression: implications for thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 107(10):e4037\u2013e4047","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"3358_CR53","doi-asserted-by":"crossref","first-page":"e20","DOI":"10.1210\/clinem\/dgaa684","volume":"106","author":"R Fernando","year":"2021","unstructured":"Fernando R, Smith TJ (2021) Slit2 regulates hyaluronan & cytokine synthesis in fibrocytes: potential relevance to thyroid-associated ophthalmopathy. J Clin Endocrinol Metab 106(1):e20\u2013e33","journal-title":"J Clin Endocrinol Metab"},{"issue":"4","key":"3358_CR54","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.ophtha.2021.10.017","volume":"129","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Kahaly GJ, Ugradar S et al (2022) Teprotumumab efficacy, safety, and durability in longer-duration thyroid eye disease and re-treatment: OPTIC-X study. Ophthalmology 129(4):438\u2013449","journal-title":"Ophthalmology"},{"issue":"2","key":"3358_CR55","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1136\/bjophthalmol-2020-317806","volume":"106","author":"AP Jain","year":"2022","unstructured":"Jain AP, Gellada N, Ugradar S et al (2022) Teprotumumab reduces extraocular muscle and orbital fat volume in thyroid eye disease. Br J Ophthalmol 106(2):165\u2013171","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"3358_CR56","doi-asserted-by":"crossref","first-page":"325","DOI":"10.4103\/tjo.tjo_30_22","volume":"12","author":"MO Adetunji","year":"2022","unstructured":"Adetunji MO, Nguyen BJ, McGeehan B et al (2022) Effect of teprotumumab on intraocular pressure in thyroid-associated ophthalmopathy. Taiwan J Ophthalmol 12(3):325\u2013329","journal-title":"Taiwan J Ophthalmol"},{"issue":"8","key":"3358_CR57","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1038\/s41433-021-01593-z","volume":"36","author":"S Ugradar","year":"2022","unstructured":"Ugradar S, Kang J, Kossler AL et al (2022) Teprotumumab for the treatment of chronic thyroid eye disease. Eye (Lond) 36(8):1553\u20131559","journal-title":"Eye (Lond)"},{"issue":"4","key":"3358_CR58","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1111\/ceo.14208","volume":"51","author":"S Ugradar","year":"2023","unstructured":"Ugradar S, Zimmerman E, Parunakian E et al. (2023) Change in lacrimal gland volume and aqueous tear production following treatment with teprotumumab. Clin Exp Ophthalmol 51(4): 339\u2013348","journal-title":"Clin Exp Ophthalmol"},{"issue":"2","key":"3358_CR59","doi-asserted-by":"crossref","first-page":"e491","DOI":"10.1097\/WNO.0000000000001298","volume":"42","author":"MJ Lopez","year":"2022","unstructured":"Lopez MJ, Herring JL, Thomas C et al (2022) Visual recovery of dysthyroid optic neuropathy with teprotumumab. J Neuroophthalmol 42(2):e491\u2013e493","journal-title":"J Neuroophthalmol"},{"issue":"4","key":"3358_CR60","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1210\/clinem\/dgac627","volume":"108","author":"L Amarikwa","year":"2023","unstructured":"Amarikwa L, Mohamed A, Kim SH et al (2023) Teprotumumab-related hyperglycemia. J Clin Endocrinol Metab 108(4):858\u2013864","journal-title":"J Clin Endocrinol Metab"},{"key":"3358_CR61","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ajo.2022.02.015","volume":"240","author":"CM Sears","year":"2022","unstructured":"Sears CM, Azad AD, Amarikwa L, Pham BH, Men CJ, Kaplan DN, Liu J, Hoffman AR et al (2022) Hearing dysfunction after treatment with teprotumumab for thyroid eye disease. Am J Ophthalmol 240:1\u201313. https:\/\/doi.org\/10.1016\/j.ajo.2022.02.015","journal-title":"Am J Ophthalmol"},{"issue":"5","key":"3358_CR62","doi-asserted-by":"crossref","first-page":"1164","DOI":"10.1002\/ohn.174","volume":"168","author":"E Kay-Rivest","year":"2023","unstructured":"Kay-Rivest E, Belinsky I, Kozlova A et al (2023) Prospective assessment of otologic adverse events due to teprotumumab: preliminary results. Otolaryngol Head Neck Surg 168(5):1164-1169","journal-title":"Otolaryngol Head Neck Surg"},{"issue":"8","key":"3358_CR63","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1007\/s40262-021-01003-3","volume":"60","author":"Y Xin","year":"2021","unstructured":"Xin Y, Xu F, Gao Y et al (2021) Pharmacokinetics and exposure-response relationship of teprotumumab, an insulin-like growth factor-1 receptor-blocking antibody. Thyr Eye Disease Clin Pharmacokinet 60(8):1029\u20131040","journal-title":"Thyr Eye Disease Clin Pharmacokinet"},{"issue":"4","key":"3358_CR64","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1001\/jamaophthalmol.2021.6284","volume":"140","author":"RS Douglas","year":"2022","unstructured":"Douglas RS, Dailey R, Subramanian PS et al (2022) Proptosis and diplopia response with teprotumumab and placebo vs the recommended treatment regimen with intravenous methylprednisolone in moderate to severe thyroid eye disease: a meta-analysis and matching-adjusted indirect comparison. JAMA Ophthalmol 140(4):328\u2013335","journal-title":"JAMA Ophthalmol"},{"key":"3358_CR65","doi-asserted-by":"crossref","unstructured":"Douglas RS, Kahaly GJ, Patel A et al (2020) Teprotumumab for the treatment of active thyroid eye disease. N Engl J Med 382(4):341\u2013352","DOI":"10.1056\/NEJMoa1910434"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-024-03358-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-024-03358-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T15:47:38Z","timestamp":1741880858000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-024-03358-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,22]]},"references-count":65,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["3358"],"URL":"https:\/\/doi.org\/10.1007\/s10792-024-03358-5","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,22]]},"assertion":[{"value":"12 September 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 November 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"435"}}